Aurobindo Pharma Ltd. Earnings/Conference Calls

Aurobindo Pharma Ltd. earnings concalls and investor presentations

Load latest

13 Aug 2020

1092.30

0.77%

Earnings Call Transcript - Q1FY21 for Aurobindo Pharma

Conference Call with Aurobindo Pharma Management and Analysts on Q1FY21 Performance and Outlook. Listen to the full earnings transcript.

Aurobindo Pharma Ltd.

12 Aug 2020

1092.30

0.77%

Investor Presentation

AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Please refer to our letter dated August 10, 2020 wherein we have intimated the schedule of Investors/ Analysts call on August 13, 2020. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first Quarter ended June 30, 2020. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/

pdf

Aurobindo Pharma Ltd.

18 Jun 2020

1092.30

0.77%

Earnings Call

AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Please refer to our letter dated June 1, 2020 wherein we have intimated the schedule of Investors/Analysts call on June 4, 2020. We are attaching herewith the Transcript of the analyst / investor call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2020 and the same is being uploaded on the website of the Company and is available in the following web link: https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/

pdf

Aurobindo Pharma Ltd.

06 Jun 2020

1092.30

0.77%

Earnings Call Transcript - Q4FY20 for Aurobindo Pharma

Conference Call with Aurobindo Pharma Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full earnings transcript.

Aurobindo Pharma Ltd.

03 Jun 2020

1092.30

0.77%

Investor Presentation

AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Please refer to our letter dated June 1, 2020 wherein we have intimated the schedule of Investors/ Analysts call on June 4, 2020. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth Quarter and year ended March 31, 2020. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/

pdf

Aurobindo Pharma Ltd.

24 Feb 2020

1092.30

0.77%

Earnings Call

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Please refer to our letter dated February 3, 2020 wherein we have intimated the schedule of Investors/Analysts call on February 7, 2020. We are attaching herewith the Transcript of the analyst / investor call on the Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2019 and the same is being uploaded on the website of the Company and is available in the following web link: https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/

pdf

Aurobindo Pharma Ltd.

06 Feb 2020

1092.30

0.77%

Investor Presentation

AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Please refer to our letter dated February 3, 2020 wherein we have intimated the schedule of Investors/ Analysts call on February 7, 2020. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the third Quarter and nine months period ended December 31, 2019. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/

pdf

Aurobindo Pharma Ltd.

28 Nov 2019

1092.30

0.77%

Earnings Call

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Please refer to our letter dated November 8, 2019 wherein we have intimated the schedule of Investors/Analysts call on November 13, 2019. We are attaching herewith the Transcript of the analyst / investor call on the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2019 and the same is being uploaded on the website of the Company and is available in the following web link: https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/

pdf

Aurobindo Pharma Ltd.

12 Nov 2019

1092.30

0.77%

Investor Presentation

AUROBINDO PHARMA LTD. - 524804 - Investor / Analysts Presentation

BSE India

Please refer to our letter dated November 8, 2019 wherein we have intimated the schedule of Investors/ Analysts call on November 13, 2019. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the second Quarter and half year ended September 30, 2019. The presentation is also being uploaded in the following weblink. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/

pdf

Aurobindo Pharma Ltd.

19 Aug 2019

1092.30

0.77%

Earnings Call

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Please refer to our letter dated August 5, 2019 wherein we have intimated the schedule of Investors/Analysts call on August 8, 2019. We are attaching herewith the Transcript of the analyst / investor call on the Unaudited Financial Results of the Company for the first quarter ended June 30, 2019 and the same is being uploaded on the website of the Company and is available in the following web link: https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/

pdf

Is Aurobindo Pharma Ltd. worth buying?

1258 Votes:

Buy 80.29%

Sell 13.75%

Hold 5.96%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf